Clinical Trial Update: Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide [Phase 2]

View source ↗

Summary

Phase 2 trial comparing cabazitaxel versus switch to alternative AR-targeted therapy (enzalutamide or abiraterone) in metastatic castration-resistant prostate c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Cabazitaxel (cabazitaxel)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2019-06-21